Jura Bio introduced VISTA, an AI data loop system for large-scale de novo antibody design, addressing gaps in functional annotation crucial for drug discovery. The system synergizes genomic medicines with generative AI for efficient protein engineering relevant to cancer therapy. Separately, a partnership between TileDB and Databricks aims to integrate multiomics and AI-driven healthcare data platforms, enhancing the capability of pharmaceutical companies to build advanced AI systems for drug development. These developments reflect the growing convergence of AI and bioinformatics in accelerating therapeutic discovery.